Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales ...

Merck announced yesterday that the US Food and Drug Administration (FDA) has approved its monoclonal antibody vaccine ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's existing treatment.

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

In a Phase 3 test that compared Enflonsia to Synagis, the safety of the Merck drug was comparable to the AstraZeneca product. Pfizer’s presence in RSV is through Abrysvo, a vaccine comprised of ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...